ASP Isotopes Inc. Reports $5.1 Million Revenue for Q2 2026, Net Loss Decreases to $33.6 Million

ASP Isotopes Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenue of $5.1 million for the quarter, a substantial increase from $1.2 million in the same period last year. This growth was driven by product revenue of $4.5 million, primarily from the sale of nuclear medical doses and collaboration revenue of $600,000. For the first half of 2026, total revenue reached $9.3 million, compared to $2.3 million in the first half of 2025. However, the company also reported a net loss of $33.6 million for the quarter, a decrease from a loss of $75.1 million in the prior year, indicating improved operational efficiency despite ongoing challenges.

The company’s operating expenses surged to $35.7 million for the quarter, up from $12.5 million a year earlier, largely due to increased research and development costs and higher selling, general, and administrative expenses. Research and development expenses alone rose to $6.8 million, reflecting the company's commitment to advancing its isotope enrichment technologies. The increase in operational costs is attributed to the acquisitions of Renergen and East Coast Nuclear Pharmacy, which have expanded ASP Isotopes' operational footprint and capabilities.

In terms of strategic developments, ASP Isotopes completed the acquisition of Renergen in January 2026, enhancing its position in the helium and LNG markets. The Virginia Gas Project, which is part of Renergen's operations, is expected to contribute significantly to the company's revenue stream. Additionally, the company has initiated plans for further geographic expansion, targeting new isotope enrichment plants in South Africa, Iceland, and the United States. The company is also pursuing collaborations with TerraPower for uranium enrichment, which could position it favorably in the nuclear fuel market.

Operationally, ASP Isotopes has seen an increase in customer engagement, with a notable rise in accounts receivable from $1.1 million at the end of 2025 to $3.0 million by June 30, 2026. The company’s total assets increased to $572.0 million, up from $498.0 million at the end of 2025, reflecting its growth trajectory and investment in infrastructure. The employee headcount has also expanded, aligning with the company's growth strategy and operational needs.

Looking ahead, ASP Isotopes anticipates continued revenue growth driven by its isotope production and the commercialization of enriched isotopes. However, the company acknowledges the need for additional capital to support its operations and expansion plans, particularly for the Virginia Gas Project's Phase 2, which is estimated to require approximately $1.16 billion. The company is actively exploring various financing options, including equity and debt financing, to ensure it can meet its operational and developmental goals.